Levosert® – preferred IUS
Formulary Changes – Progestogen only Intra-uterine Systems
The following changes have recently been made to the NHSGGC Adult Formulary relating to progestogen only intra-uterine systems (IUSs).
- Levosert® is now the preferred levonorgestrel intra-uterine system for (reversible) contraception and/or menorrhagia in women under 45 years old. It offers contraception for up to 5 years and is the lowest acquisition cost product available for this indication.
- Mirena® is no longer the preferred choice but is retained on the Formulary for contraception and/or menorrhagia and is licensed for use up to 5 years for this indication.
- Mirena® remains the preferred intra-uterine delivery system in endometrial hyperplasia and/or endometrial protection during oestrogen replacement therapy. Levosert® is not licensed for this indication. Mirena® is licensed for use up to 4 years for this indication. Please also see Faculty of Sexual and Reproductive Healthcare (FSRH) guidance here.
- Jaydess® is being discontinued and has been removed from the Formulary.
Note: Levosert® and Mirena® are progestogen only IUSs which release levonorgestrel. They should be prescribed by brand name.
Published 15/01/2020. Medicines Update blogs are correct at the time of publication.